Communication of the meeting of Transparency Council No. 9/2026 on 2 March 2026 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 9/2026 on 2 March 2026 during which the following resolutions were adopted:

1. At its meeting on 2 March 2026, the Transparency Council adopted position No. 28/2026 on the evaluation of Beyonttra (acoramidisum) under drug program B.162. “Treatment of patients with cardiomyopathy (ICD-10: E85, I42.1).”
2. At its meeting on 2 March 2026, the Transparency Council adopted position No. 29/2026 on the evaluation of Darzalex (daratumumab) under drug program B.54. “Treatment of patients with multiple myeloma (ICD-10: C90.0)”
3. At its meeting on 2 March 2026, the Transparency Council adopted opinion No. 24/2026 on the draft program “Prevention in the diagnosis of cataracts, glaucoma, and AMD (macular degeneration) for residents of the municipality of Konstancin-Jeziorna for the year 2026.”
4. At its meeting on 2 March 2026, the Transparency Council adopted opinion No. 25/2026 on the reimbursement of medicines containing the active substance sunitinibum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
5. At its meeting on 2 March 2026, the Transparency Council adopted opinion No. 26/2026 on the reimbursement of medicines containing the active substance imatinibum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
6. At its meeting on 2 March 2026, the Transparency Council adopted opinion No. 27/2026 on the reimbursement of medicines containing the active substance sorafenibum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
7. At its meeting on 2 March 2026, the Transparency Council adopted opinion No. 28/2026 on the reimbursement of medicines containing the active substance brentuximab vedotin for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics

Transparency Council meeting protocol >>